Gilead Sciences 

2Q Revenues: $1.3 billion, (+22%)

2Q Earnings: $442.8 million (+9%)*

YTD Revenues: $2.5 billion (+22%)

YTD Earnings: $939.0 million (+15%)

Comments: Product sales were a record $1.2 billion in the quarter driven by the antiviral franchise ($1.1 billion, up 34%), including the strong growth of Atripla and continued growth of Truvada. Atripla sales were $355.1 million (+67%) and Truvada sales were $516.1 million (+34%). R&D expenses in the quarter were $176.5 million (+30%)

*Earnings in the quarter include an after-tax stock-based compensation expense of $26.4 million and an in-process research and development expense of $7.8 million.